Hussain Nazimul, Khanna Rohit, Das Taraprasad, Narayanan Raja, Sunday Oluleye Tunji, Bansal Azad Gaurav, Reddy Rajeev
LV Prasad Eye Institute, Hyderabad, India.
Indian J Ophthalmol. 2008 Nov-Dec;56(6):465-8. doi: 10.4103/0301-4738.43366.
In India, refractive errors are a major cause of treatable blindness. Population surveys in southern India have shown prevalence of high myopia to be 4.32-4.54%. Photodynamic therapy (PDT) for choroidal neovascularization (CNV) caused by pathologic myopia is beneficial.
To report the 24 months outcome of PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes.
Prospective case series.
Review of prospectively collected data of Indian patients with pathologic myopia and subfoveal CNV treated with verteporfin therapy between 2001 and 2005 using standard regimen for PDT.
Wilcoxon signed rank test was used to see the difference in the mean letter acuity at intervals compared to baseline. Kaplan Meier Survival analysis was done to estimate the success rate of verteporfin therapy for CNV caused by pathologic myopia.
Fifteen patients (15 eyes) treated with standard fluence PDT and who had completed 24 months follow-up were analyzed. The mean spherical equivalent was -13.36 +/- 5.88 diopter. Five out of 15 eyes in six months, three out of 15 eyes at 12 months and four eyes out of 15 at 24 months had improved vision by > 10 letters. The mean number of treatment session was 2.2 in two years.
PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes is effective.
在印度,屈光不正为可治疗性失明的主要原因。印度南部的人口调查显示高度近视患病率为4.32 - 4.54%。光动力疗法(PDT)对病理性近视引起的脉络膜新生血管(CNV)有益。
报告维替泊芬光动力疗法治疗印度人眼中病理性近视所致黄斑中心凹下脉络膜新生血管24个月的结果。
前瞻性病例系列研究。
回顾2001年至2005年间采用光动力疗法标准方案治疗的印度病理性近视合并黄斑中心凹下脉络膜新生血管患者的前瞻性收集数据。
采用Wilcoxon符号秩检验观察与基线相比各时间点平均字母视力的差异。采用Kaplan - Meier生存分析评估维替泊芬治疗病理性近视所致脉络膜新生血管的成功率。
分析15例(15只眼)接受标准光通量光动力疗法且完成24个月随访的患者。平均等效球镜度数为 - 13.36 ± 5.88屈光度。15只眼中,6个月时5只眼、12个月时3只眼、24个月时4只眼视力提高超过10个字母。两年内平均治疗次数为2.2次。
维替泊芬光动力疗法治疗印度人眼中病理性近视所致黄斑中心凹下脉络膜新生血管有效。